Eurofins Scientific SE Stock
Stocks
ERF
FR0014000MR3
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Euronext Paris
11:55:00 2026-09-29 am EDT
|
5-day change | 1st Jan Change | ||
| 76.20 EUR | -3.20% |
|
-3.50% | +22.12% |
| Sep. 08 | Eurofins Scientific Downgraded by Morgan Stanley |  |
| Aug. 24 | Wall Street's Three-Way Stress Test | |
| Market Cap | 13.23B 14.99B 12.52B 11.35B 21.28B 1,438B 21.49B 150B 57.87B 734B 56.29B 55.06B 2,364B | P/E 2026 * |
25.4x | P/E 2027 * | 20.1x |
|---|---|---|---|---|---|
| Enterprise Value | 16.59B 18.8B 15.7B 14.24B 26.7B 1,804B 26.96B 188B 72.59B 921B 70.61B 69.07B 2,965B | EV / Sales 2026 * |
2.2x | EV / Sales 2027 * | 2.05x |
| Free-Float |
60.39% | Yield 2026 * |
1.05% | Yield 2027 * | 1.19% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ERF | Real-time | |
CBOE
| Real-time | ||
|
OTC Markets
| ERFSF | Delayed | |
|
Tradegate
| ESF0 | Real-time | |
|
Xetra
| ESF0 | Delayed | |
|
Börse Stuttgart
| ESF0 | Delayed | |
|
Boerse Muenchen
| ESF0 | Real-time | |
|
London S.E.
| 0MV5 | Delayed | |
|
CBOE
| 0MV5 | Real-time | |
|
Deutsche Boerse AG
| ESF0 | Delayed | |
|
Wiener Boerse
| ESF | End-of-day quote | |
|
Borsa Italiana
| 4ERF | End-of-day quote |
Last Transcript: Eurofins Scientific SE
| 1 day | -3.20% | ||
| 1 week | -3.50% | ||
| Current month | +5.05% | ||
| 1 month | +5.31% | ||
| 3 months | +11.76% | ||
| 6 months | +22.74% | ||
| Current year | +22.12% |
| 1 week | 75.28 |  | 78.92 |
| 1 month | 68.38 | | 79.22 |
| Current year | 56.84 | | 79.22 |
| 1 year | 54.86 | | 79.22 |
| 3 years | 39.47 | | 79.22 |
| 5 years | 39.47 | | 118.12 |
| 10 years | 29.82 | | 127.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 63 | 1986-12-31 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 2014-12-31 |
Christian Wurst
PRN | Corporate Officer/Principal | 54 | 2019-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 63 | 1986-12-31 |
Yves-Loïc Martin
BRD | Director/Board Member | 60 | 2014-12-31 |
Valérie Hanote
BRD | Director/Board Member | 60 | 1989-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 4/27/26 | Buy | 700 | 0.0004% | |||
| 4/19/26 | Sell | Chief Financial Officer | 3,000 | 0.0016% | ||
| 4/19/26 | Exercice | Executive/Senior Manager | 700 | 0.0004% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.20% | -3.50% | +25.33% | +42.43% | 15.54B | |
| -0.03% | +3.77% | +12.35% | +37.22% | 49.06B | |
| -0.73% | -0.41% | +48.84% | +36.72% | 44.6B | |
| +1.36% | +6.03% | +343.85% | +638.73% | 43.24B | |
| -0.47% | -0.76% | +9.75% | +103.07% | 41.73B | |
| +0.34% | +0.22% | +5.18% | +47.36% | 29.93B | |
| +1.00% | -1.28% | +24.23% | +156.93% | 17.19B | |
| -2.94% | +6.98% | +5.10% | - | 15.35B | |
| -0.86% | -4.00% | - | - | 15.11B | |
| +0.47% | +3.81% | +101.35% | +51.02% | 14.06B | |
| Average | -0.51% | +1.40% | +64.00% | +139.18% | 28.58B | |
| Weighted average by Cap. | -0.24% | +1.89% | +75.83% | +160.07% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.54B 8.54B 7.13B 6.47B 12.12B 819B 12.24B 85.53B 32.96B 418B 32.06B 31.37B 1,346B | 7.94B 9B 7.52B 6.82B 12.78B 864B 12.91B 90.17B 34.75B 441B 33.8B 33.07B 1,420B |
| Net income | 531M 602M 502M 456M 854M 57.73B 863M 6.03B 2.32B 29.48B 2.26B 2.21B 94.86B | 660M 748M 624M 566M 1.06B 71.73B 1.07B 7.49B 2.89B 36.63B 2.81B 2.75B 118B |
| Net Debt | 3.37B 3.81B 3.18B 2.89B 5.41B 366B 5.47B 38.21B 14.72B 187B 14.32B 14.01B 601B | 3.03B 3.44B 2.87B 2.6B 4.88B 330B 4.93B 34.43B 13.27B 168B 12.91B 12.63B 542B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-29 | €76.20 | -3.20% | 305,088 |
| 26-09-28 | €78.72 | +1.76% | 190,736 |
| 26-09-25 | €77.36 | -0.46% | 274,276 |
| 26-09-24 | €77.72 | +2.05% | 240,165 |
| 26-09-23 | €76.16 | -3.55% | 263,405 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ERF Stock
Select your edition
All financial news and data tailored to specific country editions
